Table 3.
Variables and cutoff | Number of studies | HR (95% CI) for subgroup | I2 | P for subgroup effect | P for subgroup difference |
---|---|---|---|---|---|
Sample sizes | |||||
<3000 | 3 | 1.12 [0.93, 1.35] | 79% | 0.23 | |
≥3000 | 3 | 1.21 [1.13, 1.30] | 0% | <0.001 | 0.46 |
Mean ages (years) | |||||
<65 | 3 | 1.09 [0.94, 1.27] | 61% | 0.24 | |
≥65 | 3 | 1.24 [1.16, 1.32] | 0% | <0.001 | 0.12 |
Male (%) | |||||
<40 | 2 | 1.22 [1.12, 1.33] | 0% | <0.001 | |
≥40 | 4 | 1.14 [1.01, 1.29] | 68% | 0.04 | 0.36 |
Adiponectin measurements | |||||
ELISA | 4 | 1.13 [1.01, 1.27] | 64% | 0.03 | |
Others | 2 | 1.25 [1.14, 1.37] | 0% | <0.001 | 0.20 |
AF confirmation | |||||
Include AF hospitalization | 5 | 1.22 [1.16, 1.29] | 0% | <0.001 | |
Not include AF hospitalization | 1 | 0.95 [0.82, 1.11] | — | 0.51 | 0.002 |
Follow-up duration (years) | |||||
<10 | 1 | 0.95 [0.82, 1.11] | — | 0.51 | |
≥10 | 5 | 1.22 [1.16, 1.29] | 0% | <0.001 | 0.002 |
AF incidence (%) | |||||
<15 | 3 | 1.09 [0.94, 1.27] | 61% | 0.24 | |
≥15 | 3 | 1.24 [1.16, 1.32] | 0% | <0.001 | 0.12 |
Quality scores | |||||
=8 | 2 | 1.18 [1.06, 1.31] | 0% | 0.003 | |
=9 | 4 | 1.16 [1.02, 1.31] | 71% | 0.02 | 0.83 |